EU/3/06/394

Table of contents

About

On 28 August 2006, orphan designation (EU/3/06/394) was granted by the European Commission to Analytica International GmbH, Germany, for autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin for the treatment of follicular lymphoma.

The sponsorship was transferred to Analytica International Inc. - Outcomes Research and Pricing, Germany, in May 2011 and subsequently to Biovest Europe Limited, United Kingdom, in September 2011.

Key facts

Active substance
Autologous tumor-derived immunoglobulin idiotype coupled to keyhole limpet haemocyanin
Medicine name
Lympreva
Disease / condition
Treatment of follicular lymphoma
Date of decision
28/08/2006
Outcome
Positive
Orphan decision number
EU/3/06/394

Sponsor's contact details

Biovest Europe Limited
Evershed House
70 Great Bridgewater St.
Manchester M1 5ES
United Kingdom
Telephone: +44 845 497 8663
Telefax: +44 845 497 8888

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating